Atlas FDA

NUVISC

FDA premarket approval P000046/S023 · decided 2014-04-10

Approval details

PMA number
P000046
Supplement
S023
Supplement type
Normal 180 Day Track No User Fee
Supplement reason
Labeling Change - Indications/instructions/shelf life/tradename
Trade name
NUVISC
Generic name
AID, SURGICAL, VISCOELASTIC
Applicant
Anika Therapeutics, Inc.
Date received
2014-01-15
Decision date
2014-04-10
Days to decision
85 days
Decision code
APPR
Product code
LZP
Advisory committee
Ophthalmic
Expedited review
No
Location
Beford, MA
Statement
APPROVAL FOR A NEW TRADE NAME. THE DEVICE, AS MODIFIED, WILL BE MARKETED UNDER THE TRADE NAME NUVISCTM AND IS INDICATED FOR USE DURING SURGERY IN THE ANTERIOR AND POSTERIOR SEGMENTS OF THE HUMAN EYE. PROCEDURES INCLUDE: CATARACT EXTRACTION, INTRAOCULAR LENS (IOL) IMPLANTATION, CORNEAL TRANSPLANTATION SURGERY, GLAUCOMA FILTERING SURGERY, AND SURGICAL PROCEDURES TO REATTACH THE RETINA.

Class III intelligence, same tools

PMAs share the API, exports and alerts with 510(k) data - watch an applicant and hear about every approval.

510(k) clearances by this applicant

RecordFirmDate
Integrity™ Implant (K250997)Anika Therapeutics, Inc.2025-06-17
Tactoset® Injectable Bone Substitute (K231968)Anika Therapeutics, Inc.2023-12-20
Integrity Implant (K223538)Anika Therapeutics, Inc.2023-08-17
Integrity™ Bone Staple Fixation System (K223860)Anika Therapeutics, Inc.2023-05-22
Anika Tissue Tack Fixation System (K222487)Anika Therapeutics, Inc.2023-05-08
Tactoset (K223915)Anika Therapeutics, Inc.2023-03-29
Tactoset Injectable Bone Substitute (K212083)Anika Therapeutics, Inc.2021-08-31
SCS 17-01 (K190956)Anika Therapeutics, Inc.2020-01-30